



Herbal Drugs with Promising Anti-*Leishmanial* Activity: New Hope for Leishmaniasis Treatment

Maryam Heidari-Kharaji,^{1,*} Alireza Badirzadeh,^{2,3} Fatemeh Khadir,⁴ Mohsen Soori,⁵ and Mohammad Ali Nilforoushzadeh¹

¹Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, IR Iran

²Department of Medical Parasitology and Mycology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

³Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences, Tehran, IR Iran

⁴Department of Pathobiology School of Veterinary Medicine, Shiraz University, Shiraz, IR Iran

⁵Department of Surgery, school of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

*Corresponding author: Maryam Heidari-Kharaji, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, IR Iran. E-mail: heidari.kh.maryam@gmail.com

Received 2016 March 30; Revised 2016 April 27; Accepted 2016 May 22.

Abstract

Context: Leishmaniasis is one of the most common parasitic diseases. Many medicinal plants have been utilized for the treatment of leishmaniasis.

Evidence Acquisition: Recent clinical trials have proven the efficacy of a number of herbal drugs. Synthetic agents and current drugs on the market have some disadvantages, such as side effects, high cost, and painful injections. Given the efficiency of herbal drugs, they can be a source of natural and harmless compounds for *Leishmania* treatment.

Results: Several researches have shown a wide range of plant extract exhibiting remarkable anti-leishmanial activity in vitro and in vivo.

Conclusions: Attempts for discovery of an effective strategy for leishmaniasis treatment with nominal side effects are being continued and herbal drugs are receiving much interest. More clinical studies should be done to investigate the efficacy and safety of herbal drugs for the production of effective and safe drugs for leishmaniasis treatment. This may also provide new hope for leishmaniasis treatment.

Keywords: Anti-Leishmanial Activity, Leishmaniasis, Medical Drugs, Plants, In vitro, In vivo

1. Context

Leishmaniasis is an important disease in tropical and subtropical areas. The disease is caused by various species of *Leishmania* parasites. Leishmaniasis is transmitted by biting of infected female sand flies (1, 2). *Leishmania* has 2 forms, amastigotes and promastigotes. Amastigotes are intracellular, without flagellum, spherical, and non-motile forms, which proliferate within the phagolysosomes of phagocytic cells like macrophages of the vertebrate host. The other form, promastigotes, are inside the sandflies, extracellular, spindle-shape, motile, and flagellated. Three clinical forms of leishmaniasis exist, including Cutaneous Leishmaniasis (CL), visceral leishmaniasis, and mucocutaneous leishmaniasis. The most common form of leishmaniasis is cutaneous leishmaniasis that involves the skin. Leishmaniasis is endemic in 98 countries and 350 million people are at the risk of infection. Leishmanicidals have to be controlled at low doses because frequently used drugs have severe side effects, and therefore drug resistance

could appear rapidly (1-4). About 90% of the CL occur in 8 countries, including Iran, Saudi Arabia, Iraq, Afghanistan, Algeria, Syria, Brazil, and Peru (2, 5, 6). From 1959, pentavalent antimony is utilized for leishmaniasis yet it has some disadvantages like toxicity, side effects, and prolonged injections (3). Accordingly, the efficacy of pentavalents has been reduced and development of resistant parasites restrict their usage (7, 8). The first line drugs for leishmaniasis treatment, such as meglumine antimoniate (Glucantime), sodium stibogluconate (Pentostam), and pentamidine (Pentacarinat) are not effective orally and prolonged injections are needed. The second line drugs like amphotericin B and pentamidine are very toxic (4, 7). Furthermore, vaccination methods have failed to enter clinical trials and still chemotherapy is temporarily the exclusive treatment strategy. Therefore, an urgent need for producing novel and more effective drugs with improved features exists, to change or supplement those in current use. Effective drugs from plant derivatives or plant ex-

tracts are expected to become a valuable source of new medicinal agents. Natural products and many compounds derived from natural sources show anti-leishmanial activities (9). It has been estimated that there are approximately 250,000 pharmaceutical plant species around the world (10). However, the biological effect of only around 6% of them have been assessed. Besides, only about less than 1% of therapeutic plant compounds have been evaluated in clinical trials (8, 11). This review attempted to provide an overview on some current medical plant with anti-leishmanial activity.

2. Evidence Acquisition

Natural agents may be a good source of chemical diversity to produce new drug modules. Synthetic agents and current drugs on the market have some disadvantages, such as side effects, high costs, and painful injections. New agents should be more efficient and non-toxic. Plant extracts, essential oils, and other useful compounds could be an effective source for producing new anti-leishmanial drugs. Recent clinical trials have proven the efficacy of some herbal drugs. Given the efficiency of herbal drugs, they can be a source of natural and harmless compounds for *Leishmania* treatment. This present review described some medicinal plants used against leishmaniasis.

3. Results

3.1. In Vitro Study of Herbal Drugs

Mothana and colleagues evaluated in vitro anti-leishmanial activity of medicinal plants against 3 forms of *leishmania* (*L. tropica*, *L. major* and *L. infantum* promastigotes. They reported that some species form the *Lamiaceae* family have anti-leishmanial effects (12). In Mahmoudvand's study, in vitro anti-leishmanial activity of different extracts of *B. vulgaris* against promastigote and amastigote of *L. tropica* and *L. infantum* was assessed in a murine macrophage model. Furthermore, they showed that *B. vulgaris* displayed effective in vitro leishmanicidal properties against *L. tropica* and *L. infantum* by the MTT assay (13). In vitro studies on activity of *Tridax procumbens* extracts against promastigotes of *Leishmania Mexicana* showed potent activity with no effect on mammalian cells (14). In vitro anti-leishmanial activity of *Urechites andrieuxii* (*Apocynaceae*) was evaluated and a significant effect was reported (15). The extracts from *Salvia verbenaca* (*L. Briq. ssp verbenaca Maire* (*S. clandestina* Batt. non L)) that have been reported in other in vitro studies, have anti-leishmanial activities; the effect of extract on parasite and cell viability was determined by the MTT assay (16). It has

been reported in the work carried out by Ezatpour et al. 2015, that *Pistacia khinjuk* from *Anacardiaceae* have in vitro anti-leishmanial effects against *Leishmania tropica* and *Leishmania major*; anti-amastigotes activity of the extracts was evaluated by counting the number of amastigotes in each macrophage by examining 100 macrophages in comparison to the positive control. The findings of this study revealed that the *P. khinjuk* triggered production of nitric oxide compared to untreated macrophages (17). Also, another research revealed that *Rhazya stricta* Decne leaves extracts were effective against *Leishmania* parasites (18). *Citrullus colocynthis* fruit extract and its fractions showed anti-leishmanial properties (19). Biological activity of different essential oils (EOs) from various plants on *Leishmania* (*L. amazonensis* promastigotes forms was investigated and the results showed that EOs were effective against *L. amazonensis* promastigotes with low cytotoxic activity against L6 cells (20). Anti-leishmanial property of *Artemisia sieberi* essential oil against *Leishmania infantum* was assessed with MTT measurements (21). However, many in vitro studies have demonstrated that a number of plants have effective anti-leishmanial activities.

3.2. In Vivo Herbal Therapy

Maleki et al.'s in vivo experiments showed that some plant extracts are effective against *Leishmania major*; the plant extracts in this research were able to increase the level of NO that suppressed the parasite (22). In vivo anti-leishmanial effects of *Pistacia khinjuk* (*Anacardiaceae*) alcoholic extract on *Leishmania tropica* and *Leishmania major* was shown by Ezatpour et al. The extract increased NO production (17). In another study in vivo potential effectiveness of *Artemisia annua* against *Leishmania* was reported (23). The methanolic extract from the leaves of the Vietnamese medicinal plant *Maesa balansae* displayed effective in vivo activity against *Leishmania infantum* with 90% reduction of liver amastigote burden (24). The experiments done by Maes et al. showed that Triterpenoid Saponin Extract (PX-6518) from the Plant *Maesa balansae* had promising in vivo anti-leishmanial potential against Species of visceral *Leishmania* in BALB/c mouse model, and 80% reduction of liver amastigote burden was reported (25). The results of another research indicated that plant extract based-ointments were effective in decreasing ulcer size in inbred mice infected with *Leishmaniamajor* and could increase production of NO that is needed for stopping parasite propagation (22). Nilforoushzhadeh et al. reported that *Thymus vulgaris*, *Achillea millefolium*, and propolis extracts had effective property in treatment of mice that were infected with Cutaneous leishmaniasis and the extracts were significantly effective in decreasing ulcer size (26). It has been reported that cutaneous leishmaniasis in BALB/c

mice was improved by alcoholic extract of *Berberis vulgaris* and could decrease the surface area of CL lesions (27). Other experimental research revealed that Artemisia essence was effective on BALB/c mice infected with *Leishmania major* promastigote and ulcers' diameter was reduced (28). It has been proven that *Tephrosia vogelii* extracts have anti-leishmanial activity on *L. major* infection in BALB/c mice with significantly larger reduction in lesion size and inhibition of parasite burden. Also, this study showed that the level of Nitric oxide produced was increased in the extract-treated groups (29). Metwally works demonstrated that Allicin has anti-leishmanial effects in BALB/c mice infected with *L. major* (30).

4. Conclusions

Leishmaniasis is a worldwide parasitic disease. Until now, no effective vaccine or drug for the treatment of Leishmaniasis has been reported. Currently, efforts are persistent to discover an effective strategy for leishmaniasis treatment with nominal side effects. Glucan-time as a standard drug has many side effects. There are still much trouble associated with leishmaniasis treatment. This review showed that herbal medicines and medicinal plants have in vivo and in vitro effectiveness against Leishmaniasis. Some species of *Fabaceae*, *Asteraceae*, *Berberidaceae*, *Apiaceae*, and *Lauraceae* families' extracts have anti-leishmanial activity and have been highly recommended by many researches. Based on the findings of these studies, medicinal plants exhibited anti-leishmanial activity with inhibitory effect in both promastigotes and amastigotes forms of *Leishmania*. Different groups of plants that have proved anti-leishmanial activity bring about hope to produce novel anti-leishmanial drugs.

References

- Kharaji MH, Doroud D, Taheri T, Rafati S. Drug Targeting to Macrophages With Solid Lipid Nanoparticles Harboring Paromomycin: an In Vitro Evaluation Against *L. major* and *L. tropica*. *AAPS PharmSciTech*. 2016;17(5):1110-9. doi: [10.1208/s12249-015-0439-1](https://doi.org/10.1208/s12249-015-0439-1). [PubMed: 26552399].
- Badirzadeh A, Taheri T, Taslimi Y, Abdossamadi Z, Heidari-Kharaji M, Gholami E, et al. Arginase activity in pathogenic and non-pathogenic species of *Leishmania* parasites. *PLoS Negl Trop Dis*. 2017;11(7). e0005774. doi: [10.1371/journal.pntd.0005774](https://doi.org/10.1371/journal.pntd.0005774). [PubMed: 28708893].
- Heidari-Kharaji M, Taheri T, Doroud D, Habibzadeh S, Badirzadeh A, Rafati S. Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against *Leishmania* in mice model. *Parasite Immunol*. 2016;38(10):599-608. doi: [10.1111/pim.12340](https://doi.org/10.1111/pim.12340). [PubMed: 27213964].
- Heidari-Kharaji M, Taheri T, Doroud D, Habibzadeh S, Rafati S. Solid lipid nanoparticle loaded with paromomycin: in vivo efficacy against *Leishmania tropica* infection in BALB/c mice model. *Appl Microbiol Biotechnol*. 2016;100(16):7051-60. doi: [10.1007/s00253-016-7422-y](https://doi.org/10.1007/s00253-016-7422-y). [PubMed: 26960322].
- Hepburn NC. Cutaneous leishmaniasis: an overview. *J Postgraduate Med*. 2003;49(1):50.
- Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. *Lancet Infect Dis*. 2007;7(9):581-96. doi: [10.1016/S1473-3099\(07\)70209-8](https://doi.org/10.1016/S1473-3099(07)70209-8). [PubMed: 17714672].
- Camacho MR, Phillipson JD, Croft SL, Solis PN, Marshall SJ, Ghazanfar SA. Screening of plant extracts for antiprotozoal and cytotoxic activities. *J Ethnopharmacol*. 2003;89(2-3):185-91. doi: [10.1016/S0378-8741\(03\)00269-1](https://doi.org/10.1016/S0378-8741(03)00269-1).
- Sen R, Chatterjee M. Plant derived therapeutics for the treatment of Leishmaniasis. *Phytomedicine*. 2011;18(12):1056-69. doi: [10.1016/j.phymed.2011.03.004](https://doi.org/10.1016/j.phymed.2011.03.004). [PubMed: 21596544].
- Jaffary F, Nilforoushzadeh MA, Moradi S, Derakhshan R, Ansari N. Concentrated Extracts of *Cassia fistula* Versus Intralesional Injection of Meglumine Antimoniate in Treatment of Acute Cutaneous Leishmaniasis. *J Skin Stem Cell*. 2014;1(1). doi: [10.17795/jssci6631](https://doi.org/10.17795/jssci6631).
- Moghaddas E, Khamesipour A, Mohebbali M, Fata A. Iranian Native Plants on Treatment of Cutaneous Leishmaniasis: A Narrative Review. *Iran J Parasitol*. 2017;12(3):312-22. [PubMed: 28979340].
- Jameel M, Islamuddin M, Ali A, Afrin F, Ali M. Isolation, characterization and antimicrobial evaluation of a novel compound N-octacosan 7beta ol, from *Fumaria parviflora* Lam. *BMC Complement Altern Med*. 2014;14:98. doi: [10.1186/1472-6882-14-98](https://doi.org/10.1186/1472-6882-14-98). [PubMed: 24621260].
- Mothana RA, Al-Musayeb NM, Al-Ajmi MF, Cos P, Maes L. Evaluation of the in vitro antiplasmodial, antileishmanial, and antitrypanosomal activity of medicinal plants used in Saudi and Yemeni traditional medicine. *Evid Base Complement Alternat Med*. 2014;2014.
- Mahmoudvand H, Sharififar F, Sharifi I, Ezatpour B, Fasihi Harandi M, Makki MS, et al. In Vitro Inhibitory Effect of *Berberis vulgaris* (Berberidaceae) and Its Main Component, Berberine against Different *Leishmania* Species. *Iran J Parasitol*. 2014;9(1):28-36. [PubMed: 25642257].
- Martin-Quintal Z, Moo-Puc R, Gonzalez-Salazar F, Chan-Bacab MJ, Torres-Tapia LW, Peraza-Sanchez SR. In vitro activity of *Tridax procumbens* against promastigotes of *Leishmania mexicana*. *J Ethnopharmacol*. 2009;122(3):463-7. doi: [10.1016/j.jep.2009.01.037](https://doi.org/10.1016/j.jep.2009.01.037). [PubMed: 19429313].
- Chan-Bacab MJ, Balanza E, Deharo E, Munoz V, Garcia RD, Pena-Rodriguez LM. Variation of leishmanicidal activity in four populations of *Urechites andrieuxii*. *J Ethnopharmacol*. 2003;86(2-3):243-7. [PubMed: 12738094].
- Et-Touys A, Fella H, Sebti F, Mniouil M, Aneb M, Elboury H, et al. In vitro Antileishmanial Activity of Extracts from Endemic Moroccan Medicinal Plant *Salvia verbenaca* (L.) Briq. ssp *verbenaca* Maire (S. clandestina Batt. non L). *Eur J Med Plants*. 2016;16(1):1-8. doi: [10.9734/ejmp/2016/27891](https://doi.org/10.9734/ejmp/2016/27891).
- Ezatpour B, Saedi Dezaki E, Mahmoudvand H, Azadpour M, Ezzatkah F. In vitro and in vivo antileishmanial effects of *Pistacia khinjuk* against *Leishmania tropica* and *Leishmania major*. *Evid Base Complement Alternat Med*. 2015;2015.
- Khan MJ, Baloch NU, Nabi S, Ahmed N, Bazai Z, Yasinzai M, et al. Antileishmanial, cytotoxic, antioxidant activities and phytochemical analysis of *Rhazya stricta* Decne leaves extracts and its fractions. *Asian J Plant Sci Res*. 2012;2(5):593-8.
- Nizam B, Sajid N, Kakar AM, Zargoona W, Al-Kahraman YM. In vitro antileishmanial, antitumor, cytotoxic activities and phyto-chemical analysis of *Citrullus colocynthis* fruit extract and its fractions. *Int J Med Aromat Plants*. 2013;3(1):78-84.
- Andrade MA, Azevedo CD, Motta FN, Santos ML, Silva CL, Santana JM, et al. Essential oils: in vitro activity against *Leishmania amazonensis*, cytotoxicity and chemical composition. *BMC Complement Altern Med*. 2016;16(1):444. doi: [10.1186/s12906-016-1401-9](https://doi.org/10.1186/s12906-016-1401-9). [PubMed: 27825341].
- Abouhosseini Tabari M, Youssefi MR, Moghaddas E, Ebrahimi MA, Nabavi Mousavi N, Naseri A. Antileishmanial activity of *Artemisia sieberi* essential oil against *Leishmania infantum* in vitro. *Adv Herb Med*. 2016;2(2):40-6.

22. Maleki F, Zarebavani M, Mohebalı M, Dayer MS, Hajialiani F, Tabatabaie F. In vitro and in vivo susceptibility of *Leishmania major* to some medicinal plants. *Asian Pac J Trop Biomed*. 2017;7(1):37–42. doi: [10.1016/j.apjtb.2016.11.008](https://doi.org/10.1016/j.apjtb.2016.11.008).
23. Mesa LE, Vasquez D, Lutgen P, Velez ID, Restrepo AM, Ortiz I, et al. In vitro and in vivo antileishmanial activity of *Artemisia annua* L. leaf powder and its potential usefulness in the treatment of uncomplicated cutaneous leishmaniasis in humans. *Rev Soc Bras Med Trop*. 2017;50(1):52–60. doi: [10.1590/0037-8682-0457-2016](https://doi.org/10.1590/0037-8682-0457-2016). [PubMed: 28327802].
24. Germonprez N, Maes L, Van Puyvelde L, Van Tri M, Tuan DA, De Kimpe N. In vitro and in vivo anti-leishmanial activity of triterpenoid saponins isolated from *Maesa balansae* and some chemical derivatives. *J Med Chem*. 2005;48(1):32–7. doi: [10.1021/jm031150y](https://doi.org/10.1021/jm031150y). [PubMed: 15633999].
25. Maes L, Vanden Berghe D, Germonprez N, Quirijnen L, Cos P, De Kimpe N, et al. In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant *Maesa balansae* against visceral leishmania species. *Antimicrob Agents Chemother*. 2004;48(1):130–6. [PubMed: 14693530].
26. Nilforoushzadeh MA, Shirani-Bidabadi L, Zolfaghari-Baghaderani A, Saberi S, Siadat AH, Mahmoudi M. Comparison of *Thymus vulgaris* (Thyme), *Achillea millefolium* (Yarrow) and propolis hydroalcoholic extracts versus systemic glucantime in the treatment of cutaneous leishmaniasis in balb/c mice. *J Vector Borne Dis*. 2008;45(4):301–6. [PubMed: 19248657].
27. Fata A, Rakhshandeh H, Berenji F, Jalalian FA. Treatment of cutaneous leishmaniasis in murine model by alcoholic extract of *Berberis vulgaris*. *Iran J Parasitol*. 2006;1(1):39–42.
28. Doroudgar A, Arbabi M, Razavi MR, Mohebalı M, Sadr F. Treatment of cutaneous leishmaniasis in murine model by hydro alcoholic essence of *Artemisia sieberi*. *J Arthropod Borne Dis*. 2008;2(2):42–7.
29. Marango SN, Khayeka-Wandabwa C, Makwali JA, Jumba BN, Choge JK, Adino EO, et al. Experimental therapeutic assays of *Tephrosia vogelii* against *Leishmania major* infection in murine model: in vitro and in vivo. *BMC Res Notes*. 2017;10(1):698. doi: [10.1186/s13104-017-3022-x](https://doi.org/10.1186/s13104-017-3022-x). [PubMed: 29208030].
30. Metwally DM, Al-Olayan EM, El-Khadragy MF, Alkathiri B. Anti-Leishmanial Activity (In Vitro and In Vivo) of Allicin and Allicin Cream Using *Leishmania major* (Sub-strain Zymowme LON4) and Balb/c Mice. *PLoS One*. 2016;11(8). e0161296. doi: [10.1371/journal.pone.0161296](https://doi.org/10.1371/journal.pone.0161296). [PubMed: 27537199].